Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Follow-Up Questions
CLRPF 주식의 가격 성능은 어떻습니까?
CLRPF의 현재 가격은 $3.15이며, 전 거래일에 decreased 0% 하였습니다.
Clarity Pharmaceuticals Ltd의 주요 사업 주제나 업종은 무엇입니까?
Clarity Pharmaceuticals Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Clarity Pharmaceuticals Ltd의 시가총액은 얼마입니까?
Clarity Pharmaceuticals Ltd의 현재 시가총액은 $1.1B입니다
Clarity Pharmaceuticals Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 8명의 분석가가 Clarity Pharmaceuticals Ltd에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
